Holen Sie sich die Stockscreener-App
6.80
3.13%
-0.22
Vorhandelsmarkt:
6.77
-0.03
-0.44%
Schlusskurs vom Vortag:
$7.02
Offen:
$6.92
24-Stunden-Volumen:
1.85M
Relative Volume:
1.54
Marktkapitalisierung:
$594.98M
Einnahmen:
Nettoeinkommen (Verlust:
$-185.15M
KGV:
-3.3575
EPS:
-2.0253
Netto-Cashflow:
$-148.72M
1W Leistung:
-13.04%
1M Leistung:
-30.47%
6M Leistung:
-58.76%
1J Leistung:
-34.43%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$6.61
$8.00
52-Wochen-Spanne:
$6.61
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
6.80 | 594.98M | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
498.50 | 126.35B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
226.30 | 90.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
778.36 | 80.14B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.30 | 51.46B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.52 | 41.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-03-19 | Fortgesetzt | Jefferies | Buy |
| 2026-02-11 | Eingeleitet | Stifel | Buy |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-12 | Bestätigt | Citigroup | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2024-01-30 | Eingeleitet | Citigroup | Buy |
| 2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-05 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-12-14 | Eingeleitet | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Bank of America Corp DE Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results - Yahoo Finance
Olema Pharmaceuticals (OLMA) Shares Drop 15% After AstraZeneca B - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 4.4%Here's Why - MarketBeat
Citi Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $59 - Moomoo
Olema Pharmaceuticals, Inc. $OLMA Shares Sold by Squarepoint Ops LLC - MarketBeat
OLMA: Phase III breast cancer trials for palazestrant target over $15B in global market opportunities - TradingView
Olema Oncology at citigroup summit: palazestrant data, delays - Investing.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 3.5%Should You Buy? - MarketBeat
Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1'27 (NASDAQ:OLMA) - Seeking Alpha
Wellington Management Group LLP Cuts Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Readystate Asset Management LP Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Bank of New York Mellon Corp Invests $2.78 Million in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals Grants Inducement Stock Options to Newly Appointed CFO Jason V. O’Byrne - Quiver Quantitative
Olema Pharmaceuticals (NASDAQ: OLMA) grants CFO 650K options expiring in 2036 - Stock Titan
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
A new finance chief gets options on 650,000 Olema shares - Stock Titan
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences - Yahoo Finance
BlackRock Inc. Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals Inc. (OLMA) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Olema Pharmaceuticals Inc. (OLMA) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Jupiter Topco LLC Takes $88.80 Million Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Bank of America Corp DE Raises Stock Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Olema Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:OLMA) - MarketBeat
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Olema Oncology appoints Jason O’Byrne as CFO - The Pharma Letter
OLMA Maintained by JP Morgan -- Price Target Lowered to $46.00 - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
Olema Pharmaceuticals, Inc. Announces Appointment of Jason O?Byrne to Chief Financial Officer, Effective August 11, 2026 - marketscreener.com
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $46 - moomoo.com
Olema Pharmaceuticals Names Jason O'Byrne as New CFO with Comprehensive Compensation Package - Kalkine Media
Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Australia
HC Wainwright Brokers Decrease Earnings Estimates for OLMA - MarketBeat
Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Canada
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer - The Manila Times
Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com UK
Olema Oncology’s New CFO Brings More Than Two Decades in Biotech - Stock Titan
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer - GlobeNewswire
Olema Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Harmon Cyrus - Moomoo
OLMA Maintains Rating by Citigroup -- Price Target Lowered to $59 - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $59.00 at Citigroup - marketbeat.com
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027 - TradingView
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating - Moomoo
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Olema Pharmaceuticals Inc-Aktie (OLMA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Harmon Cyrus | Director |
Jul 24 '26 |
Proposed Sale |
11.71 |
12,500 |
146,419 |
0 |
| Harmon Cyrus | Director |
Jul 23 '26 |
Sale |
11.58 |
12,500 |
144,738 |
715,270 |
| Harmon Cyrus | Director |
Jul 23 '26 |
Proposed Sale |
11.58 |
12,500 |
144,738 |
0 |
| Kovacs Shane William Charles | Former Officer |
Mar 16 '26 |
Proposed Sale |
16.61 |
4,166 |
69,178 |
0 |
| Kovacs Shane William Charles | Former Officer |
Mar 16 '26 |
Proposed Sale |
16.08 |
100,000 |
1,607,719 |
0 |
| Kovacs Shane William Charles | Former Officer |
Mar 11 '26 |
Proposed Sale |
15.94 |
50,000 |
796,796 |
0 |
| Kovacs Shane William Charles | Former Officer |
Mar 10 '26 |
Proposed Sale |
17.00 |
53,206 |
904,566 |
0 |
| Kovacs Shane William Charles | Former Officer |
Mar 09 '26 |
Proposed Sale |
13.45 |
241,999 |
3,254,933 |
0 |
| Mitchell Shawnte | Officer |
Mar 04 '26 |
Proposed Sale |
23.94 |
25,000 |
598,500 |
0 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER |
Mar 04 '26 |
Sale |
24.25 |
25,000 |
606,353 |
0 |
5.71%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):